CDC7 kinase inhibitors: a survey of recent patent literature (2017–2022)

References

• Sawa M, Masai H. Drug design with Cdc7 kinase: a potential novel cancer therapy target. Drug Des Devel Ther. 2009 Feb 6;2:255–264. doi: 10.2147/DDDT.S4303
   PubMedGoogle Scholar
• Liu R, Huang Y. CDC7 as a novel biomarker and druggable target in cancer. Clin Transl Oncol. 2022 Oct;24(10):1856–1864. doi: 10.1007/s12094-022-02853-4
   PubMed Web of Science ®Google Scholar
• Bonte D, Lindvall C, Liu H, et al. Cdc7-Dbf4 kinase overexpression in multiple cancers and tumor cell lines is correlated with p53 inactivation. Neoplasia. 2008 Sep;10(9):920–931. doi: 10.1593/neo.08216
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Moll J, Colotta F. Targeting cell division cycle 7 kinase: a new approach for cancer therapy. Clin Cancer Res. 2010 Sep 15;16(18):4503–4508.
   PubMed Web of Science ®Google Scholar
• Groelly FJ, Fawkes M, Dagg RA, et al. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023 Feb;23(2):78–94. doi: 10.1038/s41568-022-00535-5
   PubMed Web of Science ®Google Scholar
• Cheng B, Pan W, Xing Y, et al. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy. Eur J Med Chem. 2022 Feb 15;230:114109.
   PubMed Web of Science ®Google Scholar
• Brown JS, O’Carrigan B, Jackson SP, et al. Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discov. 2017 Jan;7(1):20–37. doi: 10.1158/2159-8290.CD-16-0860
   PubMed Web of Science ®Google Scholar
• Yang CC, Kato H, Shindo M, et al. Cdc7 activates replication checkpoint by phosphorylating the Chk1-binding domain of claspin in human cells. Elife. 2019 Dec 31;8:e50796.
   PubMed Web of Science ®Google Scholar
• Gourley C, Balmaña J, Ledermann JA, et al. Moving from poly (ADP-Ribose) polymerase inhibition to Targeting DNA repair and DNA damage response in cancer therapy. J Clin Oncol. 2019 Sep 1;37(25):2257–2269. doi: 10.1200/JCO.18.02050
   PubMed Web of Science ®Google Scholar
• Iwai K, Nambu T, Kashima Y, et al. A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197
   PubMed Web of Science ®Google Scholar
• Vanotti E, Amici R, Bargiotti A, et al. Cdc7 kinase inhibitors: pyrrolopyridinones as potential antitumor agents. 1. Synthesis and structure-activity relationships. J Med Chem. 2008 Feb 14;51(3):487–501. doi: 10.1021/jm700956r
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Valsasina B, Croci V, et al. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357–365. doi: 10.1038/nchembio.90
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Bargiotti A, Berthelsen J, et al. First Cdc7 kinase inhibitors: pyrrolopyridinones as potent and orally active antitumor agents. 2. Lead discovery. J Med Chem. 2009 Jan 22;52(2):293–307. doi: 10.1021/jm800977q
   PubMed Web of Science ®Google Scholar
• Ermoli A, Bargiotti A, Brasca MG, et al. Cell division cycle 7 kinase inhibitors: 1H-pyrrolo[2,3-b]pyridines, synthesis and structure-activity relationships. J Med Chem. 2009 Jul 23;52(14):4380–4390. doi: 10.1021/jm900248g
   PubMed Web of Science ®Google Scholar
• Menichincheri M, Albanese C, Alli C, et al. Cdc7 kinase inhibitors: 5-heteroaryl-3-carboxamido-2-aryl pyrroles as potential antitumor agents. 1. Lead finding. J Med Chem. 2010 Oct 28;53(20):7296–7315. doi: 10.1021/jm100504d
   PubMed Web of Science ®Google Scholar
• Nerviano Medical Sciences S.R.L. Substituted pyrrole carboxamides, process for their preparation and their use as kinase inhibitors. WO2022207404A1. 2022.
   Google Scholar
• Nerviano Medical Sciences S.R.L. Pyridyl- and pyrimidinyl-substituted pyrrole-, thiophene- and furane-derivatives as kinase inhibitors. WO2007110344A1. 2007.
   Google Scholar
• Hughes S, Elustondo F, Di Fonzo A, et al. Crystal structure of human CDC7 kinase in complex with its activator DBF4. Nat Struct Mol Biol. 2012 Nov;19(11):1101–1107. doi: 10.1038/nsmb.2404
   PubMed Web of Science ®Google Scholar
• Pharmacia Italia S.P.A. Preparation of pyridylpyrrole derivatives active as kinase inhibitors WO2005013986A1. 2005.
   Google Scholar
• Woods KW, Lai C, Miyashiro JM, et al. Aminopyrimidinone cdc7 kinase inhibitors. Bioorg Med Chem Lett. 2012 Mar 1;22(5):1940–1943. doi: 10.1016/j.bmcl.2012.01.041
   PubMed Web of Science ®Google Scholar
• Cancer Research Technology Ltd. Preparation and uses of pyrimidinone derivatives. WO2018055402A1. 2018.
   Google Scholar
• Cancer Research Technology Ltd. Pyrimidinone derivatives as cdc7 inhibitors. WO2018087527A1. 2018.
   Google Scholar
• Kurasawa O, Oguro Y, Miyazaki T, et al. Identification of a new class of potent Cdc7 inhibitors designed by putative pharmacophore model: synthesis and biological evaluation of 2,3-dihydrothieno[3,2-d]pyrimidin-4(1H)-ones. Bioorg Med Chem. 2017 Apr 1;25(7):2133–2147. doi: 10.1016/j.bmc.2017.02.021
   PubMed Web of Science ®Google Scholar
• Kurasawa O, Homma M, Oguro Y, et al. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: highly potent, selective, and time-dependent inhibitors of Cdc7 kinase. Bioorg Med Chem. 2017 Jul 15;25(14):3658–3670. doi: 10.1016/j.bmc.2017.04.044
   PubMed Web of Science ®Google Scholar
• Kurasawa O, Miyazaki T, Homma M, et al. Discovery of a novel, highly potent, and selective Thieno[3,2-d]pyrimidinone-based Cdc7 inhibitor with a quinuclidine moiety (TAK-931) as an orally active investigational antitumor agent. J Med Chem. 2020 Feb 13;63(3):1084–1104. doi: 10.1021/acs.jmedchem.9b01427
   PubMed Web of Science ®Google Scholar
• Zenji research laboratories. Substituted [5,6]cyclic-4(3h)-pyrimidinones as anticancer agents. WO2018217439A1. 2018.
   Google Scholar
• Zenji research laboratories. Compound and method for preparing substituted [5,6]cyclic-4(3h)-pyrimidone compound from same. WO2022134147A1. 2022.
   Google Scholar
• Schrödinger, Inc. Cyclic compounds and methods of using same. WO2021113492A1. 2021.
   Google Scholar
• Schrödinger, Inc. Cyclic compounds and methods of using same. WO2022197898A1. 2022.
   Google Scholar
• Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer. WO2022055963A1. 2022.
   Google Scholar
• Schrödinger Presents New Preclinical Data Supporting Advancement of CDC7 Inhibitor Development Candidate, SGR-2921, at American Society of Hematology 2022 Annual Meeting. Company Press Releases. [cited 2022 Dec 12]. Available from: https://ir.schrodinger.com/news-releases/news-release-details/schrodinger-presents-new-preclinical-data-supporting-advancement/
   Google Scholar
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Medshine Discovery Inc. Tetracyclic compounds as cdc7 inhibitors. WO2020239107A1. 2020.
   Google Scholar
• Medshine Discovery Inc. Tetracyclic compound used as cdc7 inhibitor. WO2021032170A1. 2021.
   Google Scholar
• Medshine Discovery Inc. Thieno [2, 3-c] pyrrole-4-one derivative. WO2022143693A1. 2022.
   Google Scholar
• Consejo Superior de Investigaciones Científicas. Cdc7-inhibiting purine derivatives and their use for the treatment of neurological conditions. WO2020058558A1. 2020.
   Google Scholar
• Rojas-Prats E, Martinez-Gonzalez L, Gonzalo-Consuegra C, et al. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: a new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem. 2021 Jan 15;210:112968.
   PubMed Web of Science ®Google Scholar
• Eli Lilly & Co. CDC7 inhibitors. WO2014143601A1. 2014.
   Google Scholar
• Cancer Research UK. A trial looking at LY3143921 hydrate for advanced cancer. [cited 2022 Jan 6]. Available from: https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-ly3143921-hydrate-for-advanced-cancer
   Google Scholar
• Gallagher PF, Naylor G, Bashir S, et al. A CRUK first-in-human phase I trial of LY3143921, a novel CDC7 inhibitor, in patients with advanced solid tumors. 2022 ASCO Annual Meeting; https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.3103
   Google Scholar
• Carna Biosciences, Inc. Novel furanone derivatives. WO2012133802A1. 2012.
   Google Scholar
• Irie T, Asami T, Sawa A, et al. Discovery of novel furanone derivatives as potent Cdc7 kinase inhibitors. Eur J Med Chem. 2017 Apr 21;130:406–418.
   PubMed Web of Science ®Google Scholar
• Irie T, Asami T, Sawa A, et al. Discovery of AS-0141, a potent and selective inhibitor of CDC7 kinase for the treatment of solid cancers. J Med Chem. 2021 Oct 14;64(19):14153–14164. doi: 10.1021/acs.jmedchem.1c01319
   PubMed Web of Science ®Google Scholar
• Carna Biosciences, Inc. FY2023 Q1 presentation. Available from: https://www.carnabio.com/output/irlibrary/722_en.pdf
   Google Scholar
• A Clinical Study of TQB3824 in Subjects With Advanced Cancer. ClinicalTrials.gov Identifier: NCT05028218.
   Google Scholar
• Li G, Zhang X, Yang L, et al. Abstract 1970: preclinical candidate TQB3824, a small molecule inhibitor of CDC7, shows strong antitumor efficacy in colorectal and pancreatic tumor models. Cancer Res. 2021;81(13_Supplement):1970. doi: 10.1158/1538-7445.AM2021-1970
   Web of Science ®Google Scholar
• Sloan-Kettering Institute for Cancer Research. Cdc7 kinase inhibitors and uses thereof. WO2011112635A1. 2011.
   Google Scholar
• Frattini MG, Regales L, Santos R, et al. Cdc7 inhibition as a novel approach for pancreas cancer therapy. 2013 ASCO Annual Meeting; https://ascopubs.org/doi/abs/10.1200/jco.2013.31.15_suppl.e15059
   Google Scholar
• Lin Bioscience, Inc. Lin BioScience Company presentation 202209, Available from: https://www.linbioscience.com/Investors
   Google Scholar
• Hartwell LH. Genetic control of the cell division cycle in yeast. II. Genes controlling DNA replication and its initiation. J Mol Biol. 1971 Jul 14;59(1):183–194.
   PubMed Web of Science ®Google Scholar
• Patterson M, Sclafani RA, Fangman WL, et al. Molecular characterization of cell cycle gene CDC7 from Saccharomyces cerevisiae. Mol Cell Biol. 1986 May;6(5):1590–1598. doi: 10.1128/MCB.6.5.1590
   PubMed Web of Science ®Google Scholar
• Sclafani RA. Cdc7p-Dbf4p becomes famous in the cell cycle. J Cell Sci. 2000 Jun;113(Pt 12):2111–2117. doi: 10.1242/jcs.113.12.2111
   PubMed Web of Science ®Google Scholar
• A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors. ClinicalTrials.gov Identifier: NCT03261947.
   Google Scholar
• Kuboki Y, Shimizu T, Yonemori K, et al. Safety, tolerability, and pharmacokinetics of TAK-931, a cell division cycle 7 inhibitor, in patients with advanced solid tumors: a phase I first-in-human study. Cancer Res Commun. 2022 Nov 14;2(11):1426–1435. doi: 10.1158/2767-9764.CRC-22-0277
   PubMedGoogle Scholar
• Iwai K, Nambu T, Dairiki R, et al. Molecular mechanism and potential target indication of TAK-931, a novel CDC7-selective inhibitor. Sci Adv. 2019 May 22;5(5):eaav3660. doi: 10.1126/sciadv.aav3660
   PubMed Web of Science ®Google Scholar
• Koltun ES, Tsuhako AL, Brown DS, et al. Discovery of XL413, a potent and selective CDC7 inhibitor. Bioorg Med Chem Lett. 2012 Jun 1;22(11):3727–3731. doi: 10.1016/j.bmcl.2012.04.024
   PubMed Web of Science ®Google Scholar
• Rainey MD, Bennett D, O’Dea R, et al. ATR restrains DNA synthesis and mitotic catastrophe in response to CDC7 inhibition. Cell Rep. 2020 Sep 1;32(9):108096. doi: 10.1016/j.celrep.2020.108096
   PubMed Web of Science ®Google Scholar
• Liachko NF, McMillan PJ, Guthrie CR, et al. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013 Jul;74(1):39–52. doi: 10.1002/ana.23870
   PubMed Web of Science ®Google Scholar
• Vaca G, Martinez-Gonzalez L, Fernandez A, et al. Therapeutic potential of novel cell division cycle kinase 7 inhibitors on TDP-43-related pathogenesis such as frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). J Neurochem. 2021 Feb;156(3):379–390. doi: 10.1111/jnc.15118
   PubMed Web of Science ®Google Scholar